- Home
- CTO vs ARCT Comparison
CTO vs ARCT Comparison
Compare CTO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- ARCT
- Stock Information
- Founded
- CTO 1902
- ARCT 2013
- Country
- CTO United States
- ARCT United States
- Employees
- CTO N/A
- ARCT N/A
- Industry
- CTO Real Estate Investment Trusts
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- ARCT Health Care
- Exchange
- CTO Nasdaq
- ARCT Nasdaq
- Market Cap
- CTO 569.2M
- ARCT 526.5M
- IPO Year
- CTO N/A
- ARCT N/A
- Fundamental
- Price
- CTO $16.90
- ARCT $9.30
- Analyst Decision
- CTO Strong Buy
- ARCT Buy
- Analyst Count
- CTO 3
- ARCT 10
- Target Price
- CTO $22.00
- ARCT $35.25
- AVG Volume (30 Days)
- CTO 297.5K
- ARCT 2.2M
- Earning Date
- CTO 10-28-2025
- ARCT 11-10-2025
- Dividend Yield
- CTO 8.99%
- ARCT N/A
- EPS Growth
- CTO N/A
- ARCT N/A
- EPS
- CTO N/A
- ARCT N/A
- Revenue
- CTO $146,948,000.00
- ARCT $122,122,000.00
- Revenue This Year
- CTO $21.41
- ARCT N/A
- Revenue Next Year
- CTO $8.49
- ARCT $34.32
- P/E Ratio
- CTO N/A
- ARCT N/A
- Revenue Growth
- CTO 23.84
- ARCT N/A
- 52 Week Low
- CTO $15.07
- ARCT $8.04
- 52 Week High
- CTO $20.88
- ARCT $24.17
- Technical
- Relative Strength Index (RSI)
- CTO 65.69
- ARCT 30.23
- Support Level
- CTO $16.02
- ARCT $9.36
- Resistance Level
- CTO $17.49
- ARCT $12.10
- Average True Range (ATR)
- CTO 0.36
- ARCT 1.35
- MACD
- CTO 0.14
- ARCT -0.97
- Stochastic Oscillator
- CTO 68.72
- ARCT 0.74
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.